LY3023414
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Cancer
Conditions
Endometrial Cancer, Recurrent Endometrial Cancer
Trial Timeline
Sep 1, 2015 → Mar 23, 2022
NCT ID
NCT02549989About LY3023414
LY3023414 is a phase 2 stage product being developed by Eli Lilly for Endometrial Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02549989. Target conditions include Endometrial Cancer, Recurrent Endometrial Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02536586 | Phase 1 | Completed |
| NCT02549989 | Phase 2 | Completed |
Competing Products
20 competing products in Endometrial Cancer